- Poster presentation
- Open Access
IL-12 primed CD8+ T-cells possess enhanced persistence and anti-tumor efficacy because of greater IL-7 responsiveness
© Johnson et al; licensee BioMed Central Ltd. 2013
- Published: 7 November 2013
- Irradiate Mouse
- Effector Phase
- Great Expansion
- Molecule STAT5
- Adoptive Cell Transfer
Ex vivo IL-12 priming of tumor-reactive CD8+ T-cells enhances their persistence and subsequent anti-tumor efficacy upon adoptive cell transfer (ACT) into lymphodepleted mice. Since IL-7 and IL-15 are considered critical for the persistence of adoptively transferred T-cells, we investigated the responsiveness of IL-12 primed CD8+ T-cells to these homeostatic cytokines to help elucidate the mechanisms behind their superior anti-tumor abilities. Using pmel-1 T-cell receptor transgenic mice, we found that pmel CD8+ T cells activated in the presence of IL-12 (pmelIL-12) showed much greater expansion in an irradiated (6 Gy) host compared to cells activated without IL-12 (pmelsham). This expansion was dependent on host IL-7, but not IL-15. Compared to pmelsham, pmelIL-12 demonstrated greatly enhanced in vitro IL-7 responsiveness, as measured by proliferation and phosphorylation of signaling molecules STAT5, S6 and AKT. These striking differences were not seen with IL-15. Despite not playing a major role in pmelIL-12 effector phase expansion, IL-15 was critical for maximum anti-tumor efficacy of pmelIL-12, as irradiated mice devoid of IL-15, like mice receiving IL-7 neutralizing antibody (clone M25), showed reduced survival compared to irradiated mice receiving pmelIL-12 only. This decreased tumor control likely occurred because IL-15 was needed for long-term persistence of pmelIL-12. Together, these findings suggest that IL-12 priming of CD8+ T-cells augments the efficacy of ACT protocols in part by conferring an enhanced ability to respond to IL-7, thereby enabling transferred cells to persist in the IL-7 rich post-lymphodepletion environment.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.